|Bid||26.01 x N/A|
|Ask||26.01 x N/A|
|Day's range||25.65 - 26.13|
|52-week range||19.69 - 31.17|
|Beta (5Y monthly)||1.08|
|PE ratio (TTM)||11.12|
|Earnings date||02 Aug 2023|
|Forward dividend & yield||0.92 (3.57%)|
|Ex-dividend date||18 May 2023|
|1y target est||36.60|
German healthcare group Fresenius SE lifted its earnings target for generic hospital drugs unit Kabi, citing demand for blood plasma products and clinical nutrition and the planned launches of generic biotech drugs in the United States. Kabi's 2023 sales, adjusted for currency swings, would likely grow by a "mid-single-digit" percentage, where it had previously predicted a "low-to mid-single-digit" gain, Fresenius said ahead of an investor event on Thursday. It is now targeting an operating profit margin over sales of about 14%, up from about 13% seen previously.
Investing.com -- With a price increase of 1.30%, Fresenius shares (ETR:FREG) ranked second in the German benchmark DAX index on Thursday. Positive share price impetus was provided by a capital market day in London centered around its pharmaceuticals and medical technology subsidiary Kabi.
FRANKFURT (Reuters) -German healthcare group Fresenius SE will slash costs and proceed with plans to cede strategic control over struggling dialysis group Fresenius Medical Care (FMC) as its new CEO seeks to simplify the diversified healthcare group, it said. The move comes after Elliott Investment Management took a stake in Fresenius last year, sparking speculation the activist investor might push for a break-up of the company. "This is an inflection point for Fresenius," Chief Executive Michael Sen said on Tuesday.
German healthcare group Fresenius SE said on Thursday it was potentially ready to cede control over Fresenius Medical Care (FMC), after a fall in earnings at the world's largest dialysis company. Shares in FMC were down 3.4% at 1538 GMT, while Fresenius stock surged 4.3% after it said it was considering de-consolidating the subsidiary, meaning its sales would no longer be fully integrated into its financial reports. Elliott Investment Management took a stake in Fresenius SE in October, a person familiar with the matter told Reuters at the time, sparking speculation the activist investor might push for a break up of the diversified healthcare company.
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Newly appointed Fresenius CEO Michael Sen said that the company's debt-financed growth strategy cannot continue, in an interview in Frankfurter Allgemeine Zeitung's Wednesday edition. Regarding Elliott Investment Management's stake in the company announced last week, Sen said: "We have already been in contact with Elliott." Fresenius management will include the opinion of investors regarding the future of the company in its considerations, he said, adding that no banks had been mandated for the sale of its hospital operator Helios.
FRANKFURT (Reuters) -Elliott Investment Management has taken a stake in Fresenius SE, a person familiar with the matter told Reuters on Wednesday, sparking speculation the activist investor might push for a break up of the diversified healthcare company. Fresenius and Elliott were not immediately available for comment. Shares in Fresenius, which is controlled by charitable trust Else Kroener Fresenius-Stiftung, were up 9% at 1202 GMT.
The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.